SuperworthKiniksa Pharmaceuticals International EPS KNSA
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- $0.97
- Latest quarter, Q2 FY26
- $0.30
- +30% on a year earlier
- Fiscal year 2025
- $0.74
Kiniksa Pharmaceuticals International's earnings per share was $0.97 over the twelve months to Jun 30, 2026, up 2325% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.30, up 30% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.74 | n/a |
| FY2024 | −$0.61 | −439% |
| FY2023 | $0.18 | −93% |
| FY2022 | $2.59 | n/a |
| FY2021 | −$2.30 | n/a |
| FY2020 | −$2.58 | n/a |
| FY2019 | −$3.02 | n/a |
| FY2018 | −$8.95 | n/a |
| FY2017 | −$33.25 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.30 | +30% | $0.97 | |
| Q1 FY26 | $0.27 | +145% | $0.90 | |
| Q4 FY25 | $0.17 | n/a | $0.74 | |
| Q3 FY25 | $0.23 | n/a | $0.45 | |
| Q2 FY25 | $0.23 | n/a | $0.04 | |
| Q1 FY25 | $0.11 | n/a | −$0.25 | |
| Q4 FY24 | −$0.12 | −134% | −$0.61 | |
| Q3 FY24 | −$0.18 | n/a | −$0.14 | |
| Q2 FY24 | −$0.06 | −129% | −$0.16 | |
| Q1 FY24 | −$0.25 | n/a | $0.11 | |
| Q4 FY23 | $0.35 | +483% | $0.18 | |
| Q3 FY23 | −$0.20 | −106% | −$0.11 |
Against its peers
Companies in Drug Manufacturers - General nearest Kiniksa Pharmaceuticals International's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| TGTXTG Therapeutics | $2.74 | +641% a year |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| ARQTArcutis Biotherapeutics | $0.22 | |
| CORTCorcept Therapeutics | $0.42 | −63% a year |
| LQDALiquidia | $1.39 | |
| OGNOrganon | $0.77 | −71% a year |
| Peer median | $0.90 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Kiniksa Pharmaceuticals International
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.